Pentixapharm Reports Q2 and H1 2026 Results and Advances Phase 3 Program

Pentixapharm Holding AG, a biotech firm in Berlin, reported its second quarter and first half of 2026 financial results. The company highlighted progress on its Phase 3 PANDA cardiovascular program and oncology pipeline, following regulatory milestones that advanced PANDA toward Phase 3 initiation. Revenue for H1 2026 was €0, a decrease from €38,000 in 2025. Net loss reduced to €6.9 million, down from €8.4 million the previous year. Pentixapharm also saw a decrease in operating losses and achieved a capital increase of €20.4 million for future projects.

The FDA granted Fast Track designation to Pentixapharm's lead program, [⁶⁸Ga]Ga-PentixaFor, aimed at diagnosing primary aldosteronism, paving the way for expedited discussions with regulators. In oncology, the company's CXCR4-targeted theranostic programs are moving into clinical stages, with ongoing trials evaluating new treatments for leukemia and multiple myeloma.

Pentixapharm remains on track with its plans to commence the PANDA Phase 3 study in the second half of 2026. The company continues to optimize resources, focus on strategic developments, and expand its footprint in the United States.